Yale University

Single Cell Technology, Inc.

Boston University

Mark Jay Shlomchik

James O Bowlby, Jr

Chun-Nan Chen

Richard Aleck Jorgensen

Stephen G Emerson

Ann Marshak-Rothstein

Elizabeth A Leadbetter

Ian R Rifkin

Warren D Shlomchik

The invention is a methodology which makes it possible to select from a very large number of cells, a single cell or cells of interest and obtain specific information from those cells in a rapid and efficient manner. As an example of the methodology, a large number of antibody producing cells such as plasma cells are separated so that these individual antibody producing plasma cells are placed in individual wells. The cells are allowed to produce antibodies and the antibodies in the wells are then contacted with a protein bound to a solid surface such as a well top. The protein universally and specifically binds antibodies in the wells. The surface or well tray top includes addresses configured such that each address is specifically related to one of the individual wells containing a cell producing antibodies.

Method of obtaining antibodies of interest and nucleotides encoding same

The present invention provides methods and compositions for treating immune complex associated diseases (ICAD), such as SLE, rheumatoid arthritis, and hepatitis-C related immune complex disease (e.g., cryoglobulinemia) in a subject having an ICAD or at risk for developing ICAD. The invention is based upon the surprising finding that chromatin-containing immune complexes activate autoreactive B cells and dendritic cells by a dual receptor engagement process which, in both cell types, involves a Toll-like receptor (TLR). The methods of treating ICAD comprise administering a compound to an individual in need thereof that either 1) inhibits formation of the immune complex either by preventing formation and/or binding to the TLR, or 2) interferes with binding of an autoantigen-containing immune complex (or the antigenic component thereof) to the TLR, or 3) inhibits signaling pathways initiated by dual engagement of BCR and TLR (in B cells) or FcR and TLR (in dendritic cells) via immune complexed or uncomplexed autoantigens.

Method and composition for treating immune complex associated disorders

The invention includes compositions and methods for depleting antigen presenting cells, or for impairing the biological function of antigen presenting cells, which compositions are useful for treatment of graft versus host disease and other immune diseases.

Prevention of immunoreactivity by depleting or inhibiting antigen presenting cells

Growing community of inventors

Woodbridge, CT, United States of America

Mark Jay Shlomchik